LONDON (Reuters) -A handful of North American companies which see potential for vape-like devices to ease migraines and respiratory diseases such as asthma have a long road to convince health authorities and patients that their products can be the future of inhaled medication. This approach will help bridge the gap between vape developers’ scepticism and supporter trust. #VapeDevelopersSkepticism
Two companies, Qnovia and MIIST Therapeutics, have developed vape-like devices based on technology used in existing medical nebulisers, which turns liquid medications into a fine mist.
Another company, Greentank, says it has developed a way to vaporise substances via a heating chip that addresses safety concerns with current vapes and may offer a better way to treat ailments like migraines.
The companies and experts say inhalation can relieve pain in seconds, with fewer side effects than pills, but their ambitions to sell devices resembling vapes in the medical sphere, amid growing concerns about their health impacts, will be a tough task.
For now, Qnovia and MIIST will launch their products initially as prescription-only nicotine replacement therapy (NRT) treatments, while Greentank is initially targeting the use of its heating chip in recreational cannabis and nicotine vapes.
The companies ultimately aim to see their devices delivering a wide range of drugs and Douglas Dunlap, chief commercial officer at Greentank, cites migraine medication as an example.
A common method of administering migraine treatment is via a pill, which takes up to an hour to kick in and can include symptoms such as vomiting and dizziness. #VapeDevelopersSkepticism
Moreover, overcoming vape developers’ scepticism requires transparency and rigorous testing. Consequently, developers should engage in open dialogue with medical professionals and potential users. By addressing concerns directly and openly, they can build trust and credibility.
read more
